AKERO THEREP.INC.DL-0001 (0K4 F) stock market data APIs
€38.5521
0(0%)
as of September 12, 2025
Try our APIs with
free plan!
AKERO THEREP.INC.DL-0001 Financial Data Overview
Price chart is built with
Anychart
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Prev. Close
38.5521
Open
38.5521
High
38.5521
Low
38.5521
52 wk Range
21.19-55.1
Market Cap
3 071 M
Shares Outstanding
79 989 K
EPS
-0.83
Beta
-0.243
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get AKERO THEREP.INC.DL-0001 data using free add-ons & libraries
Get AKERO THEREP.INC.DL-0001 Fundamental Data
AKERO THEREP.INC.DL-0001 Fundamental data includes:
- Net Revenue:
- EBITDA: -321 457 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: -0.72
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AKERO THEREP.INC.DL-0001 News
New
Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Akero Therapeutics, Inc. (AKRO) one of those stocks right now? By taking a look a...
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for p...
Does Akero Therapeutics (AKRO) Have the Potential to Rally 59.14% as Wall Street Analysts Expect?
Akero Therapeutics, Inc. (AKRO) closed the last trading session at $48.12, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Akero Therapeutics Inc. Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
